Cargando…

A novel prognostic score to assess the risk of progression in relapsing−remitting multiple sclerosis patients

BACKGROUND: At the patient level, the prognostic value of several features that are known to be associated with an increased risk of converting from relapsing−remitting (RR) to secondary phase (SP) multiple sclerosis (MS) remains limited. METHODS: Among 262 RRMS patients followed up for 10 years, we...

Descripción completa

Detalles Bibliográficos
Autores principales: Pisani, Anna Isabella, Scalfari, Antonio, Crescenzo, Francesco, Romualdi, Chiara, Calabrese, Massimiliano
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8360167/
https://www.ncbi.nlm.nih.gov/pubmed/33835665
http://dx.doi.org/10.1111/ene.14859
_version_ 1783737692058550272
author Pisani, Anna Isabella
Scalfari, Antonio
Crescenzo, Francesco
Romualdi, Chiara
Calabrese, Massimiliano
author_facet Pisani, Anna Isabella
Scalfari, Antonio
Crescenzo, Francesco
Romualdi, Chiara
Calabrese, Massimiliano
author_sort Pisani, Anna Isabella
collection PubMed
description BACKGROUND: At the patient level, the prognostic value of several features that are known to be associated with an increased risk of converting from relapsing−remitting (RR) to secondary phase (SP) multiple sclerosis (MS) remains limited. METHODS: Among 262 RRMS patients followed up for 10 years, we assessed the probability of developing the SP course based on clinical and conventional and non‐conventional magnetic resonance imaging (MRI) parameters at diagnosis and after 2 years. We used a machine learning method, the random survival forests, to identify, according to their minimal depth (MD), the most predictive factors associated with the risk of SP conversion, which were then combined to compute the secondary progressive risk score (SP‐RiSc). RESULTS: During the observation period, 69 (26%) patients converted to SPMS. The number of cortical lesions (MD = 2.47) and age (MD = 3.30) at diagnosis, the global cortical thinning (MD = 1.65), the cerebellar cortical volume loss (MD = 2.15) and the cortical lesion load increase (MD = 3.15) over the first 2 years exerted the greatest predictive effect. Three patients’ risk groups were identified; in the high‐risk group, 85% (46/55) of patients entered the SP phase in 7 median years. The SP‐RiSc optimal cut‐off estimated was 17.7 showing specificity and sensitivity of 87% and 92%, respectively, and overall accuracy of 88%. CONCLUSIONS: The SP‐RiSc yielded a high performance in identifying MS patients with high probability to develop SPMS, which can help improve management strategies. These findings are the premise of further larger prospective studies to assess its use in clinical settings.
format Online
Article
Text
id pubmed-8360167
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-83601672021-08-17 A novel prognostic score to assess the risk of progression in relapsing−remitting multiple sclerosis patients Pisani, Anna Isabella Scalfari, Antonio Crescenzo, Francesco Romualdi, Chiara Calabrese, Massimiliano Eur J Neurol Dementia and Cognitive Disorders BACKGROUND: At the patient level, the prognostic value of several features that are known to be associated with an increased risk of converting from relapsing−remitting (RR) to secondary phase (SP) multiple sclerosis (MS) remains limited. METHODS: Among 262 RRMS patients followed up for 10 years, we assessed the probability of developing the SP course based on clinical and conventional and non‐conventional magnetic resonance imaging (MRI) parameters at diagnosis and after 2 years. We used a machine learning method, the random survival forests, to identify, according to their minimal depth (MD), the most predictive factors associated with the risk of SP conversion, which were then combined to compute the secondary progressive risk score (SP‐RiSc). RESULTS: During the observation period, 69 (26%) patients converted to SPMS. The number of cortical lesions (MD = 2.47) and age (MD = 3.30) at diagnosis, the global cortical thinning (MD = 1.65), the cerebellar cortical volume loss (MD = 2.15) and the cortical lesion load increase (MD = 3.15) over the first 2 years exerted the greatest predictive effect. Three patients’ risk groups were identified; in the high‐risk group, 85% (46/55) of patients entered the SP phase in 7 median years. The SP‐RiSc optimal cut‐off estimated was 17.7 showing specificity and sensitivity of 87% and 92%, respectively, and overall accuracy of 88%. CONCLUSIONS: The SP‐RiSc yielded a high performance in identifying MS patients with high probability to develop SPMS, which can help improve management strategies. These findings are the premise of further larger prospective studies to assess its use in clinical settings. John Wiley and Sons Inc. 2021-05-05 2021-08 /pmc/articles/PMC8360167/ /pubmed/33835665 http://dx.doi.org/10.1111/ene.14859 Text en © 2021 The Authors. European Journal of Neurology published by John Wiley & Sons Ltd on behalf of European Academy of Neurology https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Dementia and Cognitive Disorders
Pisani, Anna Isabella
Scalfari, Antonio
Crescenzo, Francesco
Romualdi, Chiara
Calabrese, Massimiliano
A novel prognostic score to assess the risk of progression in relapsing−remitting multiple sclerosis patients
title A novel prognostic score to assess the risk of progression in relapsing−remitting multiple sclerosis patients
title_full A novel prognostic score to assess the risk of progression in relapsing−remitting multiple sclerosis patients
title_fullStr A novel prognostic score to assess the risk of progression in relapsing−remitting multiple sclerosis patients
title_full_unstemmed A novel prognostic score to assess the risk of progression in relapsing−remitting multiple sclerosis patients
title_short A novel prognostic score to assess the risk of progression in relapsing−remitting multiple sclerosis patients
title_sort novel prognostic score to assess the risk of progression in relapsing−remitting multiple sclerosis patients
topic Dementia and Cognitive Disorders
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8360167/
https://www.ncbi.nlm.nih.gov/pubmed/33835665
http://dx.doi.org/10.1111/ene.14859
work_keys_str_mv AT pisaniannaisabella anovelprognosticscoretoassesstheriskofprogressioninrelapsingremittingmultiplesclerosispatients
AT scalfariantonio anovelprognosticscoretoassesstheriskofprogressioninrelapsingremittingmultiplesclerosispatients
AT crescenzofrancesco anovelprognosticscoretoassesstheriskofprogressioninrelapsingremittingmultiplesclerosispatients
AT romualdichiara anovelprognosticscoretoassesstheriskofprogressioninrelapsingremittingmultiplesclerosispatients
AT calabresemassimiliano anovelprognosticscoretoassesstheriskofprogressioninrelapsingremittingmultiplesclerosispatients
AT pisaniannaisabella novelprognosticscoretoassesstheriskofprogressioninrelapsingremittingmultiplesclerosispatients
AT scalfariantonio novelprognosticscoretoassesstheriskofprogressioninrelapsingremittingmultiplesclerosispatients
AT crescenzofrancesco novelprognosticscoretoassesstheriskofprogressioninrelapsingremittingmultiplesclerosispatients
AT romualdichiara novelprognosticscoretoassesstheriskofprogressioninrelapsingremittingmultiplesclerosispatients
AT calabresemassimiliano novelprognosticscoretoassesstheriskofprogressioninrelapsingremittingmultiplesclerosispatients